Investors
Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Key information
2019 Full year and fourth quarter results announcement
Latest information
Press releases
- GSK delivers 2019 sales of £33.8 billion +10% AER, +8% CER (Pro-forma +4% CER*)
- CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
- GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
Annual Report 2018
We published our Annual Report 2018 on 12 March 2019. View the summary and download the full report or individual sections.